Vedolizumab Biosimilar(Rophibio)

N/A

Report date: 2024/07/31 15:37:50

Base Information

Drug NameVedolizumab Biosimilar(Rophibio)

Drug Alias NameRBS-004

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsMucosal addressin cell adhesion molecule-1 inhibitors

TargetsIntegrin alpha-4/beta-7Mucosal addressin cell adhesion molecule-1

Therapy Area/IndicationsInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRophibio Inc

China Registration ClassN/A

Active CompaniesRophibio Inc

Inactive CompaniesN/A

Active IndicationsInflammatory Bowel Diseases

Inactive IndicationsN/A

ATC CodeL04AG05